{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=82", "query": { "intervention": "Continuous Dose", "page": 82 }, "page_size": 10 }, "pagination": { "page": 82, "page_size": 10, "total_count": 5326, "total_pages": 533, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=83&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=81&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T14:43:32.909Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04594772", "title": "Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreas Cancer" ], "interventions": [ { "name": "Folfirinox", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "Pancreatectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2021-03-17", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-11-12T14:43:32.909Z", "location_count": 2, "location_summary": "Tucson, Arizona • Cincinnati, Ohio", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04594772" }, { "nct_id": "NCT01417195", "title": "Menopur Mixed Protocol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Infertility" ], "interventions": [ { "name": "Bravelle", "type": "DRUG" }, { "name": "Menopur", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "42 Years", "sex": "FEMALE", "summary": "18 Years to 42 Years · Female only" }, "enrollment_count": 122, "start_date": "2011-07", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2014-05-16", "last_synced_at": "2026-11-12T14:43:32.909Z", "location_count": 10, "location_summary": "Lone Tree, Colorado • Clearwater, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Lone Tree", "state": "Colorado" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Naperville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01417195" }, { "nct_id": "NCT00873275", "title": "Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "ursodiol", "type": "DRUG" }, { "name": "RNA analysis", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "positron emission tomography (PET)", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2009-03-11", "completion_date": "2025-02-26", "has_results": false, "last_update_posted_date": "2025-06-22", "last_synced_at": "2026-11-12T14:43:32.909Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00873275" }, { "nct_id": "NCT01061112", "title": "Effects of Genotype on CYP2C9 Drug Interactions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Healthy" ], "interventions": [ { "name": "Flurbiprofen Control - Flurbiprofen Only", "type": "DRUG" }, { "name": "Flurbiprofen Inhibition - Flurbiprofen & Fluconazole", "type": "DRUG" }, { "name": "Ketoprofen Control - Ketoprofen Only", "type": "DRUG" }, { "name": "Ketoprofen Inhibition - Ketoprofen & Fluconazole", "type": "DRUG" }, { "name": "Tolbutamide Control - Tolbutamide Only", "type": "DRUG" }, { "name": "Tolbutamide Inhibition - Tolbutamide & Fluconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 23, "start_date": "2009-12", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2019-07-18", "last_synced_at": "2026-11-12T14:43:32.909Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01061112" }, { "nct_id": "NCT02077881", "title": "Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Indoximod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 157, "start_date": "2014-08", "completion_date": "2018-10-17", "has_results": true, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-11-12T14:43:32.909Z", "location_count": 11, "location_summary": "Palo Alto, California • Augusta, Georgia • Lexington, Kentucky + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Paramus", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02077881" }, { "nct_id": "NCT04225039", "title": "Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "INCMGA00012", "type": "DRUG" }, { "name": "INCAGN01876", "type": "DRUG" }, { "name": "SRS", "type": "DRUG" }, { "name": "Brain surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2020-06-23", "completion_date": "2029-04-30", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-11-12T14:43:32.909Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04225039" }, { "nct_id": "NCT04774419", "title": "Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Intensity modulated radiation therapy (IMRT)", "type": "RADIATION" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Hypofractionated IMRT", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 62, "start_date": "2021-04-02", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-12T14:43:32.909Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04774419" }, { "nct_id": "NCT00406419", "title": "A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1015, "start_date": "2006-12-27", "completion_date": "2015-04-22", "has_results": true, "last_update_posted_date": "2020-11-27", "last_synced_at": "2026-11-12T14:43:32.909Z", "location_count": 1, "location_summary": "South San Francisco, California", "locations": [ { "city": "South San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00406419" }, { "nct_id": "NCT00436657", "title": "Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peritoneal Neoplasms", "Retroperitoneal Neoplasms", "Gastrointestinal Neoplasms", "Adenocarcinoma", "Neuroblastoma", "Ovarian Neoplasms", "Sarcoma", "Adrenocortical Carcinoma", "Wilms Tumor", "Rhabdomyosarcoma", "Desmoplastic Small Round Cell Tumor" ], "interventions": [ { "name": "CHPP of Cisplatin", "type": "DRUG" }, { "name": "Abdominal Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 10, "start_date": "2007-02", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2012-04-02", "last_synced_at": "2026-11-12T14:43:32.909Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436657" }, { "nct_id": "NCT00444912", "title": "The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma", "Hodgkin Disease" ], "interventions": [ { "name": "G-CSF plus plerixafor", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2006-02", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2014-03-13", "last_synced_at": "2026-11-12T14:43:32.909Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00444912" } ] }